Dijana Djureinovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3282545/publications.pdf

Version: 2024-02-01

20 papers 17,096 citations

16 h-index 21 g-index

22 all docs 22 docs citations

times ranked

22

38695 citing authors

#	Article	IF	Citations
1	Agonistic CD40 Antibodies in Cancer Treatment. Cancers, 2021, 13, 1302.	3.7	50
2	A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research, 2021, 27, 4757-4767.	7.0	44
3	Infiltration of NK and plasma cells is associated with a distinct immune subset in nonâ€small cell lung cancer. Journal of Pathology, 2021, 255, 243-256.	4.5	17
4	Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung. BMC Cancer, 2019, 19, 741.	2.6	10
5	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	30.7	75
6	Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal of Thoracic Oncology, 2019, 14, 628-640.	1,1	54
7	Expression of scavenger receptor <scp>MARCO</scp> defines a targetable tumorâ€associated macrophage subset in nonâ€small cell lung cancer. International Journal of Cancer, 2018, 143, 1741-1752.	5.1	65
8	Multispectral imaging for quantitative and compartmentâ€specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. Journal of Pathology, 2018, 244, 421-431.	4.5	159
9	An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1–Positive Lung Adenocarcinomas. Journal of Thoracic Oncology, 2018, 13, 1676-1691.	1.1	21
10	Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer. Lung Cancer, 2018, 125, 157-163.	2.0	16
11	A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma. BMC Cancer, 2017, 17, 9.	2.6	27
12	Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. Modern Pathology, 2017, 30, 964-977.	5.5	17
13	The Human Adrenal Gland Proteome Defined by Transcriptomics and Antibody-Based Profiling. Endocrinology, 2017, 158, 239-251.	2.8	25
14	A pathology atlas of the human cancer transcriptome. Science, 2017, 357, .	12.6	2,570
15	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Modern Pathology, 2017, 30, 1411-1421.	5.5	151
16	The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. Journal of Thoracic Oncology, 2016, 11, 862-872.	1.1	70
17	Profiling cancer testis antigens in non–small-cell lung cancer. JCI Insight, 2016, 1, e86837.	5.0	82
18	Tissue-based map of the human proteome. Science, 2015, 347, 1260419.	12.6	10,802

#	Article	IF	CITATIONS
19	A systematic analysis of commonly used antibodies in cancer diagnostics. Histopathology, 2014, 64, 293-305.	2.9	13
20	Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics. Molecular and Cellular Proteomics, 2014, 13, 397-406.	3.8	2,819